---
title: "Stocks in Play: Oncolytics Biotech Inc"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292586160.md"
description: "03:51 AM EST - Oncolytics Biotech Inc : Provided a clinical and regulatory update on REO 033, the Company’s randomized controlled study evaluating pelareorep in combination with folinic acid, fluorouracil and irinotecan and bevacizumab for the second-line treatment of patients with Rat Sarcoma-mutant, microsatellite stable metastatic colorectal cancer. Oncolytics Biotech Inc sharesNCY are trading up $0.04 at $0.92.Full Press Release:"
datetime: "2026-07-14T07:55:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292586160.md)
  - [en](https://longbridge.com/en/news/292586160.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292586160.md)
generator: "portal-rs"
---

# Stocks in Play: Oncolytics Biotech Inc

**03:51 AM EST - Oncolytics Biotech Inc :** Provided a clinical and regulatory update on REO 033, the Company’s randomized controlled study evaluating pelareorep in combination with folinic acid, fluorouracil and irinotecan and bevacizumab for the second-line treatment of patients with Rat Sarcoma-mutant, microsatellite stable metastatic colorectal cancer. Oncolytics Biotech Inc shares N.ONCY are trading **up $0.04** at $0.92.  

*Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=7774334928205890*

### Related Stocks

- [ONCY.US](https://longbridge.com/en/quote/ONCY.US.md)

## Related News & Research

- [Oncolytics says FDA aligns on pivotal expansion path for REO 033 colorectal cancer trial](https://longbridge.com/en/news/296232477.md)
- [Oncolytics reports FDA Type D meeting and rapid progress in randomized REO 033 colorectal cancer trial](https://longbridge.com/en/news/292494699.md)
- [Oil Rises on Reports US Will Reject Recent Iran Deal](https://longbridge.com/en/news/297336863.md)
- [Stocks in Play: Oncolytics Biotech Inc](https://longbridge.com/en/news/284230718.md)
- [Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $5.00 by Analysts at HC Wainwright](https://longbridge.com/en/news/296357626.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**